-

09:02:07 PM

VERU Stock News

VERU - Veru Inc

10/13/21 8:30 AM

Nasdaq : VERU

clinical trial

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

RHEA-AI

very positive

09/20/21 8:30 AM

Nasdaq : VERU

clinical trial

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin

RHEA-AI

neutral

09/09/21 8:30 AM

Nasdaq : VERU

clinical trial

Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the Phase 1b/2 study of sabizabulin (VERU-111) in

RHEA-AI

neutral

09/08/21 8:30 AM

Nasdaq : VERU

conferences

Veru to Present at Three Upcoming Healthcare Investment Conferences

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the following upcoming healthcare investor

RHEA-AI

neutral

08/12/21 6:30 AM

Nasdaq : VERU

earnings

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter

Late Clinical Stage Oncology Drug

RHEA-AI

neutral

07/29/21 8:30 AM

Nasdaq : VERU

conferencesearnings

Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 third quarter on

RHEA-AI

neutral

06/28/21 8:30 AM

Nasdaq : VERU

clinical trial

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin

RHEA-AI

neutral

06/25/21 8:30 AM

Nasdaq : VERU

clinical trial

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer

In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resistant prostate cancer patients who have also become resistant to abiraterone or enzalutamide, but

RHEA-AI

neutral

06/10/21 8:30 AM

Nasdaq : VERU

clinical trial

Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company

RHEA-AI

neutral

06/07/21 8:30 AM

Nasdaq : VERU

clinical trial

Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting

Companion diagnostic test to measure AR may be used to select

RHEA-AI

neutral

VERU Data:

IndustryPharmaceutical Preparation Manufacturing
Websiteverupharma.com
CeoMitchell Steiner
Security nameVeru Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees339
Tags
- Consumer Non-Durables
- Household/Personal Care
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address48 NW 25th St Ste 102
StateFlorida
CityMiami
Zip33127-4442
CountryUnited States
Phone13125959123

VERU Description:

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.